Rxsight vs Lantheus: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Rxsight Inc (RXST)

Q3 20266 Jul – 13 Aug 2026

▲2▼2

Alcon Deal Brings Cash but Core Lens Sales Slump Forces Guidance Withdrawal

Alcon partnership: $60M upfront, up to $140M milestones, royalties RxSight will co-develop adjustable lenses with Alcon, getting $60 million upfront, up to $140 million more if milestones are met, and royalties on sales. Alcon handles global selling. This validates RxSight's technology and gives cash and a bigger reach, which supports the stock.
This is the biggest new positive force for RXST this period.
Core Light Adjustable Lens sales fall 19%, guidance withdrawn Second-quarter product sales excluding Alcon dropped 19% to $27.2 million, lens unit volumes fell 9%, and gross margin slipped. The company withdrew its 2026 guidance and now expects to give new guidance in early 2027. This weak core business is the main reason the stock is under pressure.
This is the key negative driver and explains why the stock is moving down despite the Alcon deal.
Analyst downgrades and fair value cut after soft Q2 Jefferies cut its price target to $6.50 and BofA to $6.50 with an Underperform rating after Q2 sales missed expectations. The modelled fair value fell from $9.93 to $8.43. These downgrades reflect lower growth and profit assumptions, which weigh on the stock price.
Analyst reactions show how the weak quarter changed professional expectations for RXST.
Alcon's strong Q2 and IOL demand support collaboration outlook Alcon reported 7% sales growth, raised its EPS outlook, and said its premium lens adoption is strong. Alcon also discontinued a competing lens program and highlighted the RxSight collaboration. A healthy partner with commercial reach improves the odds the co-developed lenses succeed, a longer-term positive for RxSight.
Alcon's health and commitment are a real counterweight to RxSight's own weak sales.

July 20266 Jul – 13 Aug 2026

▲2▼2

Alcon Deal Brings Cash but Core Lens Sales Slump Forces Guidance Withdrawal

Alcon partnership: $60M upfront, up to $140M milestones, royalties RxSight will co-develop adjustable lenses with Alcon, getting $60 million upfront, up to $140 million more if milestones are met, and royalties on sales. Alcon handles global selling. This validates RxSight's technology and gives cash and a bigger reach, which supports the stock.
This is the biggest new positive force for RXST this period.
Core Light Adjustable Lens sales fall 19%, guidance withdrawn Second-quarter product sales excluding Alcon dropped 19% to $27.2 million, lens unit volumes fell 9%, and gross margin slipped. The company withdrew its 2026 guidance and now expects to give new guidance in early 2027. This weak core business is the main reason the stock is under pressure.
This is the key negative driver and explains why the stock is moving down despite the Alcon deal.
Analyst downgrades and fair value cut after soft Q2 Jefferies cut its price target to $6.50 and BofA to $6.50 with an Underperform rating after Q2 sales missed expectations. The modelled fair value fell from $9.93 to $8.43. These downgrades reflect lower growth and profit assumptions, which weigh on the stock price.
Analyst reactions show how the weak quarter changed professional expectations for RXST.
Alcon's strong Q2 and IOL demand support collaboration outlook Alcon reported 7% sales growth, raised its EPS outlook, and said its premium lens adoption is strong. Alcon also discontinued a competing lens program and highlighted the RxSight collaboration. A healthy partner with commercial reach improves the odds the co-developed lenses succeed, a longer-term positive for RxSight.
Alcon's health and commitment are a real counterweight to RxSight's own weak sales.

Latest6 Jul – 13 Aug 2026

▲2▼2

Alcon Deal Brings Cash but Core Lens Sales Slump Forces Guidance Withdrawal

Alcon partnership: $60M upfront, up to $140M milestones, royalties RxSight will co-develop adjustable lenses with Alcon, getting $60 million upfront, up to $140 million more if milestones are met, and royalties on sales. Alcon handles global selling. This validates RxSight's technology and gives cash and a bigger reach, which supports the stock.
This is the biggest new positive force for RXST this period.
Core Light Adjustable Lens sales fall 19%, guidance withdrawn Second-quarter product sales excluding Alcon dropped 19% to $27.2 million, lens unit volumes fell 9%, and gross margin slipped. The company withdrew its 2026 guidance and now expects to give new guidance in early 2027. This weak core business is the main reason the stock is under pressure.
This is the key negative driver and explains why the stock is moving down despite the Alcon deal.
Analyst downgrades and fair value cut after soft Q2 Jefferies cut its price target to $6.50 and BofA to $6.50 with an Underperform rating after Q2 sales missed expectations. The modelled fair value fell from $9.93 to $8.43. These downgrades reflect lower growth and profit assumptions, which weigh on the stock price.
Analyst reactions show how the weak quarter changed professional expectations for RXST.
Alcon's strong Q2 and IOL demand support collaboration outlook Alcon reported 7% sales growth, raised its EPS outlook, and said its premium lens adoption is strong. Alcon also discontinued a competing lens program and highlighted the RxSight collaboration. A healthy partner with commercial reach improves the odds the co-developed lenses succeed, a longer-term positive for RxSight.
Alcon's health and commitment are a real counterweight to RxSight's own weak sales.

Lantheus Holdings Inc (LNTH)

Q3 202626 Jun – 14 Aug 2026

▲2▼1

Curium's $8B buyout and new FDA approval reshape Lantheus

Curium agrees to acquire Lantheus for up to $8 billion Curium will pay $102.50 per share in cash plus up to $12 more if sales targets are met, a 14.9% premium. This puts a firm floor under the stock and is the main reason it trades near the offer price.
The buyout is the single biggest force driving LNTH's price and future value.
FDA approves Tauklarify for tau PET imaging The FDA approved Tauklarify, a new imaging agent for Alzheimer's tau pathology. This adds a new product to Lantheus's portfolio and could support the contingent value rights tied to future sales.
A new FDA approval is a fresh positive catalyst that can affect the buyout's contingent payments.
FDA rejects LNTH-2501 due to third-party facility issues The FDA issued a Complete Response Letter for LNTH-2501, a PET diagnostic for neuroendocrine tumors, because of unresolved manufacturing issues at a partner's facility. This delays a potential product but does not question the drug's data.
This is a fresh regulatory setback that could weigh on sentiment and future growth prospects.

July 202626 Jun – 14 Aug 2026

▲2▼1

Curium's $8B buyout and new FDA approval reshape Lantheus

Curium agrees to acquire Lantheus for up to $8 billion Curium will pay $102.50 per share in cash plus up to $12 more if sales targets are met, a 14.9% premium. This puts a firm floor under the stock and is the main reason it trades near the offer price.
The buyout is the single biggest force driving LNTH's price and future value.
FDA approves Tauklarify for tau PET imaging The FDA approved Tauklarify, a new imaging agent for Alzheimer's tau pathology. This adds a new product to Lantheus's portfolio and could support the contingent value rights tied to future sales.
A new FDA approval is a fresh positive catalyst that can affect the buyout's contingent payments.
FDA rejects LNTH-2501 due to third-party facility issues The FDA issued a Complete Response Letter for LNTH-2501, a PET diagnostic for neuroendocrine tumors, because of unresolved manufacturing issues at a partner's facility. This delays a potential product but does not question the drug's data.
This is a fresh regulatory setback that could weigh on sentiment and future growth prospects.

Latest26 Jun – 14 Aug 2026

▲2▼1

Curium's $8B buyout and new FDA approval reshape Lantheus

Curium agrees to acquire Lantheus for up to $8 billion Curium will pay $102.50 per share in cash plus up to $12 more if sales targets are met, a 14.9% premium. This puts a firm floor under the stock and is the main reason it trades near the offer price.
The buyout is the single biggest force driving LNTH's price and future value.
FDA approves Tauklarify for tau PET imaging The FDA approved Tauklarify, a new imaging agent for Alzheimer's tau pathology. This adds a new product to Lantheus's portfolio and could support the contingent value rights tied to future sales.
A new FDA approval is a fresh positive catalyst that can affect the buyout's contingent payments.
FDA rejects LNTH-2501 due to third-party facility issues The FDA issued a Complete Response Letter for LNTH-2501, a PET diagnostic for neuroendocrine tumors, because of unresolved manufacturing issues at a partner's facility. This delays a potential product but does not question the drug's data.
This is a fresh regulatory setback that could weigh on sentiment and future growth prospects.